Biotech Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Business Update
AEterna Zentaris completes distribution of remaining shares of Atrium Biotechnologies
January 29th, 2007
AEterna Zentaris, Inc., (AEZ; AEZS) a growing global biopharmaceutical company focused on endocrine therapy and oncology, has completed the special distribution in kind of all of the 11,052,996 subordinate voting shares of the capital of Atrium Biotechnologies, Inc., (ATB) previously held by AEterna Zentaris by way of return of capital that was approved at the company's special meeting of shareholders held on December 15, 2006. Gilles Gagnon, AEterna Zentaris president and CEO commented: "Over the past year, not only did we successfully advance our pipeline to late-stage development, but we also set the stage to become a pure play biopharmaceutical company by spinning...
Source: Biotech Business Week (2007-01-29)
|
